688266.SHG Suzhou Zelgen Biopharmaceuticals Co Ltd

Healthcare Biotechnology Shanghai Stock Exchange
91.09 CNY
Close of Nov 5, 2026
75.10 160.00
Market cap
CNY 24.1B
P/E
42.6x
P/B
12.87x
ROE
49.5%
Dividend yield
0.11%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 688266.SHG undervalued?

Graham number

The Graham number of Suzhou Zelgen Biopharmaceuticals Co Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Suzhou Zelgen Biopharmaceuticals Co Ltd fundamental analysis

No fundamental analysis for Suzhou Zelgen Biopharmaceuticals Co Ltd yet.

Suzhou Zelgen Biopharmaceuticals Co Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Suzhou Zelgen Biopharmaceuticals Co Ltd

Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tosylate tablets for liver cancer, hepatocellular carcinoma, and metastatic radioactive iodine-refractory differentiated thyroid cancer; and recombinant human thrombin for hemostasis. It also develops gecacitinib hydrochloride tablets for severe alopec…

Full company profile